Elagolix for Fibroid-Associated Heavy Menstrual Bleeding
- 21 May 2020
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (21) , 2066
Abstract
To the Editor: Schlaff et al. (Jan. 23 issue)1 discuss options for the management of uterine fibroids, mentioning a variety of interventional therapies and stating that data from randomized, controlled trials show that the effectiveness of these therapies is limited. We consider this statement to be misleading. On the contrary, since the publication of the 2008 practice guidelines from the American College of Obstetricians and Gynecologists, uterine-artery embolization has been recognized as one of three surgical options with level A evidence supporting its safety and effectiveness.2-4 All patients should be counseled about this surgical alternative during the process of informed . . .Keywords
This publication has 5 references indexed in Scilit:
- Elagolix for Heavy Menstrual Bleeding in Women with Uterine FibroidsNew England Journal of Medicine, 2020
- Medical Therapies for Uterine Fibroids – A Systematic Review and Network Meta-Analysis of Randomised Controlled TrialsPLOS ONE, 2016
- ACOG Practice Bulletin No. 96: Alternatives to Hysterectomy in the Management of LeiomyomasObstetrics & Gynecology, 2008
- Uterine-Artery Embolization versus Surgery for Symptomatic Uterine FibroidsNew England Journal of Medicine, 2007
- Uterine artery embolization versus hysterectomy in the treatment of symptomatic uterine fibroids (EMMY trial): Peri- and postprocedural results from a randomized controlled trialAmerican Journal of Obstetrics and Gynecology, 2005